A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or equal to 750 cc and eGFR greater than or equal to 60 mL/min/1.73m2.
Inclusion Criteria:
Exclusion Criteria:
Budapest, 1115, Hungary
Szeged, 6720, Hungary
Vilnius, 08661, Lithuania
Grodzisk Mazowiecki, 05-825, Poland
Olsztyn, 10-561, Poland
Limbova 5, Bratislava Region 83305, Slovakia
Bratislava, 831 01, Slovakia
Izmir, Inciralti/ Narlidere 35340, Turkey (Türkiye)